Peptide Tools for HIV Research
About Human Immunodeficiency Virus
HIV is a retrovirus that causes acquired immuno-deficiency syndrome (AIDS). This progressive collapse of cellular immune response renders commonly harmless infections and cancers to become severe. They are caused by pathogens such as Candida, M. tuberculosis or latent herpes viruses (e.g. EBV, HCMV). In infected individuals, HIV is present as free particles and in infected immune cells (specifically CD4+ cells). Entry of HIV into cells requires the interaction of the viral envelope protein gp120 with the CD4 glycoprotein and a chemokine receptor on the host cell surface.
HIV in Research
Development of a potential vaccine is an important goal to AIDS researchers. Immune correlate analysis of the largest clinical trial so far (RV144 or Thai trial) was performed with the help of JPT’s RepliTope™ Antigen Collection HIV Microarrays. The results showed that the presence of IgG against the V2 loop of gp120 is highly correlated with reduced risk of infection. Other vaccination strategies aim to stimulate specific cytotoxic T-lymphocytes.
JPT's Peptide Tools to Study HIV:
Cellular Immune Response Profiling
JPT offers peptide libraries and peptide pools for HIV research and clinical in-vitro assays. We provide knowledgeable support, high quality, flexible and innovative formats combined with expert know-how to bring forward your research project. In addition, we offer GxP Peptides & Pools for immunotherapy and specific clinical applications at attractive pricing.
PepMix™ Peptide Pools for antigen specific stimulation of T-cells in
- Development of immunotherapies & vaccination strategies
- Assessment of vaccine efficacy & immune correlation
- Validating clinical T-cell assays
HIV Ultra PepMixes™
ENV, GAG, NEF and POL peptide pools were designed with focus on high coverage. A proprietary algorithm was used to obtain peptide combinations providing an optimal coverage of sequence variability.
Tailored HIV PepMix™ Peptide Pools
Peptide Pools tailored for your specific needs!
PepTrack™ Peptide Libraries for T-cell assays in
- Vaccine development
- High-throughput T-cell epitope discovery
- Monitoring of cellular immune response
- Clinical trials
Humoral Immune Response Profiling
JPT is the technology leader for peptide microarrays. We offer a range of premade catalog microarrays (RepliTope™) and production of customized microarrays (PepStar™). In addition, we provide full assay and analysis service. Please inquire for our service offers.
Peptide Microarrays for humoral immune response profiling in
- Immune monitoring of humoral responses
- Profiling of HIV specific samples or antibodies
- Detection of epitopes and epitope spreading
- Vaccine target identification
Catalog RepliTope™ Ultra Peptide Microarray
JPT’s HIV Ultra microarray displays overlapping peptide scans through HIV gag p17 and p24, tat, nef, env and the remaining immunogenic regions of the HIV proteome (6564 15mer peptides). It covers sequences from the most frequent clades (A, B, C, D, G, CRF1, CRF2) of HIV 1. We also offer our assay and analysis service using your samples with this high-content HIV peptide microarray.
> Catalog RepliTope™ Peptide Microarrays Product Page
Tailored PepStar™ Peptide Microarrays
You define content and layout, we provide economic and fast production in our regulated clean-room environment. We also offer our assay and analysis service using your samples with your tailored HIV peptide microarrays.
> Tailored PepStar™ Peptide Microarrays Product Page
In addition to high-content peptide microarrays, JPT offers the development of peptide based enzyme-linked immunosorbent assays (ELISA). This common analytical and highly sensitive immunological assay is well established for proteins but requires detailed experimental know-how for peptides. Peptide ELISA is offered as stand alone service for mapping of epitopes and definition of protein interaction sites or as validation assay to confirm results obtained with JPT’s peptide microarrays.
GxP Peptides & Pools
GxP Peptides & Pools
We established an enhanced production environment for GxP peptides that goes beyond ISO 9001:2015 regulations for the more stringent product requirements of immunotherapy as well as vaccine & drug development. Thus, the resulting GxP peptides and GxP peptide pools have been approved for specific clinical applications.
Selected HIV Related References
"Superior Efficacy of an HIV Vaccine Combined with ARV Prevention in SHIV Challenged Non-human Primates"
Le Grand et al., Journal of Virology (2016) – PMID: 27009957
"Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces Robust IgA-Isotype B Cell Response in Breast Milk"
Nelson et al., Journal of Virology (2016) – PMID: 26937027
"Functionally Active HIV-specific T Cells that Target gag and nef Can Be Expanded from Virus-naive Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic HSCT"
Patel et al., Biology of Blood and Marrow Transplantation (2015)
"Effect of Cytokines on Siglec-1 and HIV-1 Entry in Monocyte–derived Macrophages: the Importance of HIV-1 Envelope V1V2 Region"
Jobe et al., J Leukoc Biol. (2015) – PMID: 26667473
"Innate Immune Activity Correlates with CD4 T Cell-associated HIV-1 DNA Decline During Latency-Reversing Treatment with Panobinostat"
Olesen et al., Journal of Virology (2015) – PMID: 26223643
"Broadly-specific Cytotoxic T Cells Targeting Multiple HIV Antigens Are Expanded From HIV+ Patients: Implications for Immunotherapy"
Lam et al., Molecular Therapy (2015) – PMID: 25366030
"Conformational Instability Governed by Disulfide Bonds Partitions the Dominant From Subdominant Helper T-cell Responses Specific for HIV-1 Envelope Glycoprotein gp120"
Nguyen et al., Vaccine (2015) – PMID: 25944298
"A Comparative Phase 1 Clinical Trial to Identify Anti-infective Mechanisms of Vitamin D in People With HIV Infection"
Lachmann et al., AIDS (2015) – PMID: 25870995
"Protective Efficacy of Adenovirus-protein Vaccines Against SIV Challenges in Rhesus Monkeys"
Barouch et al., Science (2015) - PMID: 26138104
Selected HIV Related Testimonials
“The RV 144 HIV trial is considered as one of the first successful HIV vaccine trials. It has become clear that the V2 loop of gp120 is an important site for immunogenicity and protection from HIV infection. The use of JPT’s PepStarTM microarray technology has been very useful for the correlation of the clincial outcome with humoral immune responses. As have the cyclic peptides been from JPT to validate these findings!”
J. Currier, PhD., Walter Reed Army Institute, Rockville, Maryland, USA.
Selected HIV Related Application Notes
The Challenge of Antigen Sequence Diversity: Solutions with ULTRA‐Peptide Libraries
Reimer, Application Note (2015)
Developing Multi‐HIV Antigen Specific T Cells as a Component of a Cure Strategy
Gary et al., Application Note (2015)
Qualification and Use of Peptide Libraries for Clinical Trial Immunomonitoring
Cox et al., Application Note (2013)
A Modular Approach for Epitope Discovery and High-Resolution Profiling of Humoral Immune Responses
Pawlowski et al., Application Note (2013)
More application notes
Performance Control of T-cell Assays
Check the innovative, easy method to produce cellular reference samples for antigen-specific T-cell assays (TERS).
Analyze 21 Samples on a Single Microarray with our new RepliTope™ Multiwell Microarrays available for Tumor Antigens and Infections